Viridian Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Viridian Therapeutics (VRDN).

Price Target Range — 12 Quarters

Analyst Consensus — 17 Analysts

1S.Buy

14Buy

2Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$37Upside to Avg. PT+49.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 22, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$36→$38
Aug 7, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$35→$36
Aug 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$38→$39
Jun 30, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$34→$35
Jun 30, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$35→$38
Jun 30, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$32→$43
Jun 30, 2026	Needham	Serge Belanger	PT Raise	Buy	$32→$34
Jun 29, 2026	Wells Fargo	Derek Archila	Upgrade	Equal-Weight→Overweight	$20→$31
Jun 29, 2026	Needham	Serge Belanger	Maintained	Buy	$32
May 15, 2026	Evercore ISI Group	Maneka Mirchandaney	PT Cut	Outperform	$27→$26
May 6, 2026	RBC Capital	Lisa Walter	PT Raise	Outperform	$30→$34
May 5, 2026	Needham	Serge Belanger	Maintained	Buy	$32
Apr 21, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$36→$33
Apr 8, 2026	Wedbush	Laura Chico	PT Cut	Outperform	$37→$31
Apr 7, 2026	Goldman Sachs	Richard Law	PT Cut	Buy	$36→$31
Apr 7, 2026	RBC Capital	Lisa Walter	PT Cut	Outperform	$42→$30
Apr 2, 2026	Evercore ISI Group	Maneka Mirchandaney	PT Cut	Outperform	$45→$32
Mar 31, 2026	Goldman Sachs	Richard Law	PT Cut	Buy	$41→$36
Mar 31, 2026	Wedbush	Laura Chico	PT Cut	Outperform	$44→$37
Mar 31, 2026	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$29→$20

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $36 to $38.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $35 to $36.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $38 to $39.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $34 to $35.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $35 to $38.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43

Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $32 to $43.

Benzinga Newsdesk

Viridian Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Viridian Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38

PRO
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43

People Also Watch

People Also Watch

Viridian Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Viridian Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38

PRORBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36

PROTruist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39

PRORBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35

PROTruist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38

PROWedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $36

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39

PRO
RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35

PRO
Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38

PRO
Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43